Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21179291 | 1.00 | PRKCB (0.53) | PRKCBPAK4 | |
| SCHEMBL22206298 | 0.80 | PRKCB (0.75) | PRKCBPAK4 | |
| SCHEMBL22206299 | 0.78 | PRKCB (0.62) | PRKCBPAK4 | |
| SCHEMBL22217131 | 0.76 | PRKCB (0.71) | PRKCBPAK4 | |
| SCHEMBL3327623 | 0.72 | PRKCB (0.66) | PRKCBPAK4 | |
| SCHEMBL3327434 | 0.70 | PRKCB (1.00) | PRKCBPAK4 | |
| SCHEMBL3327770 | 0.67 | PRKCB (1.00) | PRKCB | |
| SCHEMBL1367931 | 0.67 | PAK4 (1.00) | PAK4 | |
| SCHEMBL7014150 | 0.65 | PRKCB (0.54) | PRKCBPAK4 | |
| SCHEMBL21143486 | 0.65 | PRKCB (0.45) | PRKCBPAK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022261214-A1 | COMPOSITIONS COMPRISING PKC-BETA INHIBITORS AND PROCESSES FOR THE PREPARATION THEREOF | MINGSIGHT PHARMACEUTICALS, INC. (US) | 2022-12-15 | — | — | WO | disclosed |
| CN-115381832-A | Treatment of cancer | 深圳明赛瑞霖药业有限公司 | 2022-11-25 | — | — | CN | disclosed |
| US-20220202815-A1 | TREATMENT OF CANCER | MINGSIGHT PHARMACEUTICALS, INC. | 2022-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220202815-A1 | TREATMENT OF CANCER | PRKACB, PRKDC, PRKCH | PRKCB 4/4885PAK4 264/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.